ORCHPHARMA.NSORCHPHARMA.NSNSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -1.47% | +9.39% | -29.25% | -13.10% | -4.64% |
| Gross Profit Growth | -6.18% | +57.89% | -21.34% | -33.34% | -30.72% |
| EBITDA Growth | -18.96% | -24.59% | -36.04% | -75.44% | -99.83% |
| Operating Income Growth | -11.89% | -6.76% | -77.04% | -147.79% | -49.97% |
| Net Income Growth | -29.41% | -33.50% | -49.20% | -121.01% | -160.71% |
| EPS Growth | -33.66% | -32.31% | -49.22% | -121.04% | -160.73% |
| EPS Diluted Growth | -33.66% | -32.31% | -49.22% | -121.04% | -160.73% |
| Weighted Average Shares Growth | +6.40% | -0.01% | +0.05% | -0.13% | -0.03% |
| Weighted Average Shares Diluted Growth | +6.40% | -0.01% | +0.05% | -0.13% | -0.03% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +20.70% | +0.00% | -6.05% | +0.00% |
| Inventory Growth | +0.00% | +23.52% | +0.00% | -4.48% | +0.00% |
| Asset Growth | +0.00% | +8.63% | +0.00% | +5.31% | +0.00% |
| Book Value per Share Growth | +3.86% | +8.37% | +8.31% | +4.19% | +0.00% |
| Debt Growth | +0.00% | +29.17% | +0.00% | +70.74% | +0.00% |
| R&D Expense Growth | +0.00% | +17.95% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +0.00% | +145.42% | -100.00% | +0.00% | -100.00% |